FDA Approves PAXLOVID — Pfizer Laboratories Div Pfizer Inc

# FDA Approves Pfizer's Paxlovid as Antiviral Treatment Pfizer announced FDA approval of Paxlovid (nirmatrelvir and ritonavir) on May 25, 2023, solidifying the company's position in the competitive COVID-19 antiviral market and potentially driving sustained demand for the combination therapy. The approval reinforces Pfizer's diversified revenue streams beyond vaccines as the company capitalizes on ongoing treatment demand in the post-pandemic era.